Working… Menu

Efficacy of Diazoxide in Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00131755
Recruitment Status : Completed
First Posted : August 19, 2005
Last Update Posted : July 18, 2011
Information provided by:
Grill, Valdemar, M.D.

Brief Summary:
The purpose of this study is to find out if Diazoxide can partly retain insulin production in newly diagnosed type 1 diabetes patients.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Drug: diazoxide Phase 4

Detailed Description:

At the time of diagnosis most subjects with type 1 diabetes retain significant endogenous insulin secretion as assessed by C-peptide measurements. Although not sufficient for the needs of the individual, residual insulin secretion is important for metabolic control, for avoidance of hypoglycemic episodes and, perhaps, for protection against diabetic complications. To retain residual endogenous insulin secretion in type 1 diabetes is thus highly desirable.

Residual insulin secretion deteriorates during the course of type 1 diabetes. The underlying autoimmune process is a major determinant of deterioration.

However, also measures that do not directly target the immune system could be beneficial. The DCCT study randomised subjects with type 1 diabetes to either intensive or conventional insulin treatment. The intensive insulin treatment markedly retarded deterioration in C-peptide levels during 5 years of observation. The favourable effect could be due to lesser hyperglycemia per se. Alternatively, the effect of intensive insulin treatment could be secondary to lesser degree of over-stimulation of the patients' beta-cells.

It is by now established that relief from over-stimulation by diazoxide favourably affects beta-cell function and that such treatment can retard a decline in residual insulin secretion in subjects with newly diagnosed type 1 diabetes. Diazoxide has been used in clinical practice for > three decades without major safety concerns.

Disturbing, albeit reversible, side effects are halting long-term studies with diazoxide in type 1 diabetes. The researchers find that lower and intermittent (i.e. night time) dosing of diazoxide produces no measurable side effects in subjects with type 2 diabetes.

This is a double blinded placebo controlled study, with 35 participants with newly diagnosed type 1 diabetes are randomised into either placebo or Diazoxide for 6 months. The patients will be followed up after intervention for at least 12 months.

Beta cell function and glycemic control will be monitored.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of 6 Months Treatment With Diazoxide at Bedtime in Preventing Beta-cell Demise in Newly Diagnosed Type 1 Diabetes
Study Start Date : February 2005
Actual Primary Completion Date : August 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1
Drug Information available for: Diazoxide

Primary Outcome Measures :
  1. Insulin secretion (measured by fasting and stimulated c-peptide) [ Time Frame: 12 months ]
  2. Glycemic control (measured by blood glucose) [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Autoimmune activity (measured by islet antibodies) [ Time Frame: 6 months ]
  2. Side effects [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 diabetes no longer than three months
  • Positive antibodies against GAD or IA2
  • Age between 18-40 years
  • C-peptide >0.2 nmol/l

Exclusion Criteria:

  • Drug or alcohol abuse
  • Severe concomitant disease
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00131755

Layout table for location information
University Hospital of Trondheim
Trondheim, Norway, 7006
Sponsors and Collaborators
Grill, Valdemar, M.D.
Layout table for investigator information
Principal Investigator: Grill Valdemar, MD PhD Norwegian University of Science and Technology
Layout table for additonal information
Responsible Party: Valdemar Grill, NTNU Identifier: NCT00131755    
Other Study ID Numbers: DIAZ 1
Eudract 2004-004103-38
First Posted: August 19, 2005    Key Record Dates
Last Update Posted: July 18, 2011
Last Verified: July 2011
Keywords provided by Grill, Valdemar, M.D.:
type 1 diabetes
beta cell rest
insulin secretion
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Antihypertensive Agents
Vasodilator Agents